Atezolizumab, nivolumab, and durvalumab indications are independent of PD-L1 expression, while pembrolizumab is restricted to patients whose tumours do not have EGFR or ALK genomic aberrations and express PD-L1 with a tumour proportion score (TPS) ≥1% determined by an FDA-approved test. The gene discussed is CD274; the disease is neoplasm.